These experimental results suggest that myricetin ameliorates hyperglycemia in T2DM through inhibition of GLUT2 in the intestine and enhancement of GLUT4 surface expression and/or activity in the muscles, and that anti-diabetic action of myricetin is relatively potent compared to other types of flavonoids such as quercetin, fisetin and luteolin. The gene discussed is SLC2A2; the disease is Hyperglycemia.